Retrospective Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Jul 6, 2020; 8(13): 2778-2786
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2778
Table 1 Demographic and clinical characteristics of the patients at baseline, n (%)
CharacteristicAGGEMP value
Age in yr57 (40-72)59 (31-67)
Sex0.787
Male19 (63)20 (67)
Female11 (37)10 (33)
Performance status0.791
019 (63.3)18 (60)
111 (36.7)12 (40)
Diabetes0.559
No23 (77)21 (70)
Yes7 (23)9 (30)
Operative procedure0.605
Pancreatoduodenectomy15 (50)17 (57)
Distal pancreatectomy15 (50)13 (43)
Residual tumor status0.687
R027 (90)26 (87)
R13 (10)4 (13)
Primary tumor status0.638
T16 (20.0)3 (10.0)
T217 (56.7)20 (66.7)
T35 (16.6)6 (20.0)
T42 (6.7)1 (3.3)
Regional lymph node status0.273
N022 (73)18 (60)
N18 (27)12 (40)
Pathological stage0.405
I (IA/IB)17 (5/12, 56.7)13 (1/12, 43.4)
II (IIA/IIB)11 (4/7, 36.6)16 (5/11, 53.3)
III2 (6.7)1 (3.3)
Tumor grade0.105
Well differentiated3 (10)2 (6.7)
Moderately differentiated23 (76.7)17 (56.7)
Poorly differentiated4 (13.3)11 (36.6)
Pre-adjuvant CA19-9, median48.224.60.795
≤ 37 U/mL13 (43.4)14 (46.7)
> 37 U/mL17 (56.6)16 (53.3)
Table 2 Adverse events with nab-paclitaxel plus gemcitabine and gemcitabine alone
AG
GEM
P valueP value
Grade 1/2 (%)Grade 3/4 (%)Grade 5 (%)Grade 1/2 (%)Grade 3/4 (%)Grade 5 (%)Grade ≥ 3
White blood cell count decreased8 (26.7)9 (30.0)07 (23.3)6 (20.0)00.5490.371
Neutropenia5 (16.7)13 (43.3)04 (13.3)9 (30.0)00.4350.284
Anemia10 (33.3)3 (10.0)06 (20.0)3 (10.0)00.4891.000
Thrombocytopenia5 (16.7)3 (10.0)02 (6.7)2 (6.7)00.3940.639
Fatigue9 (30.0)4 (13.3)06 (20.0)2 (6.7)00.3820.385
Vomiting10 (33.3)3 (10.0)1 (3.3)8 (26.7)01 (3.3)0.1680.148
Diarrhea8 (26.7)1 (3.3)06 (20.0)000.3921.000
Fever8 (26.7)2 (6.7)05 (16.7)1 (3.3)00.4960.550
Febrile neutropenia2 (6.7)4 (13.3)1 (3.3)3 (10.0)1 (3.3)00.2960.073
Infection2 (6.7)1 (3.3)1 (3.3)1 (3.3)1 (3.3)00.6150.550
Sensory neuropathy14 (46.7)15 (50.0)1 (3.3)7 (23.3)00< 0.001< 0.001